NMR characterization of weak interactions between RhoGDI2 and fragment screening hits.Liu, J., Gao, J., Li, F., Ma, R., Wei, Q., Wang, A., Wu, J., Ruan, K.
(2017) Biochim Biophys Acta 1861: 3061-3070
- PubMed: 27721047
- DOI: https://doi.org/10.1016/j.bbagen.2016.10.003
- Primary Citation of Related Structures:
- PubMed Abstract:
The delineation of intrinsically weak interactions between novel targets and fragment screening hits has long limited the pace of hit-to-lead evolution. Rho guanine-nucleotide dissociation inhibitor 2 (RhoGDI2) is a novel target that lacks any chemical probes for the treatment of tumor metastasis.
Hefei National Laboratory for Physical Science at the Microscale, School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230027, PR China. Electronic address: email@example.com.